Ferguson Wellman Capital Management Inc. decreased its position in Eli Lilly And Co (NYSE:LLY) by 3.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 28,203 shares of the company’s stock after selling 890 shares during the quarter. Ferguson Wellman Capital Management Inc.’s holdings in Eli Lilly And Co were worth $4,175,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in LLY. West Branch Capital LLC lifted its holdings in Eli Lilly And Co by 8.1% during the 3rd quarter. West Branch Capital LLC now owns 4,437 shares of the company’s stock valued at $657,000 after purchasing an additional 333 shares during the last quarter. Crewe Advisors LLC boosted its holdings in shares of Eli Lilly And Co by 30.0% in the 3rd quarter. Crewe Advisors LLC now owns 572 shares of the company’s stock worth $85,000 after acquiring an additional 132 shares in the last quarter. Old North State Trust LLC grew its position in Eli Lilly And Co by 1.9% during the 3rd quarter. Old North State Trust LLC now owns 5,767 shares of the company’s stock worth $854,000 after acquiring an additional 107 shares during the last quarter. Rhenman & Partners Asset Management AB increased its holdings in Eli Lilly And Co by 57.1% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 165,000 shares of the company’s stock valued at $24,423,000 after purchasing an additional 60,000 shares in the last quarter. Finally, Regentatlantic Capital LLC raised its position in Eli Lilly And Co by 4.4% in the 3rd quarter. Regentatlantic Capital LLC now owns 11,318 shares of the company’s stock valued at $1,675,000 after purchasing an additional 472 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.
A number of analysts have recently weighed in on LLY shares. JPMorgan Chase & Co. raised their target price on Eli Lilly And Co from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday. Morgan Stanley upgraded shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $149.55 to $176.00 in a research report on Thursday, September 3rd. They noted that the move was a valuation call. Berenberg Bank started coverage on shares of Eli Lilly And Co in a research note on Tuesday, September 29th. They issued a “hold” rating and a $144.00 target price for the company. Mizuho increased their price target on shares of Eli Lilly And Co from $155.00 to $164.00 and gave the company a “neutral” rating in a research note on Monday, June 29th. Finally, Bank of America restated a “buy” rating and issued a $180.00 price objective on shares of Eli Lilly And Co in a research report on Friday, June 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $169.62.
LLY opened at $146.12 on Friday. The company has a fifty day moving average price of $149.64 and a two-hundred day moving average price of $153.41. The firm has a market capitalization of $139.76 billion, a PE ratio of 23.72, a P/E/G ratio of 1.35 and a beta of 0.19. Eli Lilly And Co has a 52 week low of $101.36 and a 52 week high of $170.75. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.94 and a current ratio of 1.22.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Thursday, July 30th. The company reported $1.89 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.58 by $0.31. The business had revenue of $5.50 billion for the quarter, compared to analyst estimates of $5.77 billion. Eli Lilly And Co had a return on equity of 183.80% and a net margin of 24.48%. The firm’s revenue was down 2.4% on a year-over-year basis. During the same period last year, the company earned $1.50 EPS. Equities analysts forecast that Eli Lilly And Co will post 7.31 EPS for the current year.
In other news, SVP Melissa S. Barnes sold 5,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $151.01, for a total value of $755,050.00. Following the completion of the sale, the senior vice president now directly owns 23,580 shares of the company’s stock, valued at approximately $3,560,815.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.09% of the stock is currently owned by insiders.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.